Xeno Biosciences is a clinical-stage company dedicated to developing groundbreaking therapies for metabolic diseases, particularly obesity. The company operates in the healthcare and biotechnology market, targeting patients suffering from chronic and relapsing obesity. Xeno Biosciences' core product, XEN 101, is an investigational oral treatment designed to induce weight loss by mimicking the microbiome changes typically seen after gastric bypass surgery. This innovative approach has shown significant weight loss effects in both animal models and human trials, with minimal side effects. The company generates revenue through the development and eventual commercialization of its proprietary treatments. By focusing on a niche market with limited existing treatment options, Xeno Biosciences aims to provide a non-surgical alternative to bariatric surgery, addressing a significant unmet medical need.

Keywords: metabolic diseases, obesity treatment, clinical-stage, XEN 101, oral formulation, gastric bypass, weight loss, biotechnology, healthcare, innovative therapies.